ACON Laboratories received Emergency Use Authorization for its SARS-COV-2 IgG/IgM rapid test

,

On Dec. 17, 2020, ACON Laboratories announced that its SARS-COV-2 IgG/IgM Rapid Test has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.

ACONメs SARS-CoV-2 IgG/IgM Rapid Test is a lateral flow chromatographic immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human serum, plasma, and venous whole blood.

Tags:


Source: ACON Laboratories
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.